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Introduction: Primary tracheal tumors are rare, and composed of
various benign and malignant pathologies. Although nationwide
epidemiologic studies were reported in western population, study
about the oriental population is lacking. The aims of this study were
to establish the clinical manifestations and treatment outcomes of
primary tracheal tumors and explore the prognostic variables for
malignant tracheal tumors.
Methods: From January 1989 through December 2006, 37 patients
(14 with benign tumors, 23 with malignant tumors) were treated in
a tertiary referral center. Retrospective review of medical records
was performed.
Results: Benign tumors comprised of various pathologies. Except
the papilloma cases (n  3), all of them were managed successfully
without recurrence. Squamous cell carcinomas (n 11) and adenoid
cystic carcinomas (n  9) comprised most of the malignant tumors.
Clinical stage was a statistically significant prognostic variable (p 
0.016). Five-year overall survival rate was 41.1% for squamous cell
carcinoma and 45.7% for adenoid cystic carcinoma and no statisti-
cally significant difference (p  0.673) was observed.
Conclusion: Papillomas were difficult to manage, however, other
benign tumors were successfully treated. Among malignant tumors,
surgery should be considered as the first choice of treatment,
regardless of the histologic type, if the tumors are resectable.
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Primary tracheal tumors are the rare subset of tumors andusually malignant in adults (80–90%)1 and benign in
children (60–70%).2,3 The main presenting symptom is dys-
pnea, followed by other upper airway obstruction symptoms.
Reports regarding the pathologic distribution of the
benign tracheal tumor are scarce and little information is
available about their natural history and behavior.1 According
to an epidemiologic study, relatively common benign tracheal
tumors are papilloma, fibroma, and hemangioma in descend-
ing orders.4
Primary tracheal tumors account for 0.1 to 0.4% of all
malignant diseases.5 The average patient age is 60 years for
squamous cell carcinoma (SCC), and less than 50 years for
adenoid cystic carcinomas (ACC). According to an epidemi-
ologic study,6 59% of patients were men and 73% smoked.
Primary tracheal tumors can arise from the respiratory
epithelium, salivary glands, and mesenchymal structures of
the trachea. Squamous-cell carcinoma and ACC comprises
about two-thirds of adult primary tracheal tumors. The re-
maining third are distributed widely in a heterogeneous group
of malignant tumors.7
Nationwide studies were performed in some European
countries.6,8–10 However, no large scale studies regarding the
pathologic distribution and clinical behavior of tracheal tu-
mors in oriental populations have been reported. In this study,
we reviewed the pathologic distribution, demographic find-
ings and factors related with the prognosis in 37 primary
tracheal tumors.
MATERIALS AND METHODS
From January 1989 through December 2006, 37 patients
(14 with benign tumors, 23 with malignant tumors) were diag-
nosed and treated at the Seoul National University Hospital.
Retrospective review was performed including age, gender,
initial symptom, site, tumor size, lymph node involvement,
distant metastasis, histologic finding, treatment outcome, and
recurrence.
Bhattacharyya’s11 staging system was adopted and used
(Table 1). Survival analysis was estimated by the Kaplan-Meier
method and multiple regression analysis using an SPSS version
13.0 statistical program (SPSS, Inc., Chicago).
This study was approved by the Seoul National Uni-
versity College of Medicine/Seoul National University Hos-
pital Institutional Review Board.
RESULTS
Mean age was 21.7 years (0.3–57) for benign tumors
and 52.9 years (29–69) for malignant tumors. Dividing them
according to the age, all (8 of 8) childhood tracheal tumors
were benign and 79.3% (23 of 29) of adult tracheal tumors
were malignant. Mean follow-up duration was 56.3 months
(16–205). In the same study period, 87,778 patients were
diagnosed and treated for malignant tumors (4532 thoracic
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malignant tumors) and 37,088 patients (1211 thoracic benign
tumors) were managed for benign tumors in our hospital.
Malignant tracheal tumors accounted for 0.026% of all ma-
lignant disease (0.5% of all thoracic malignancies), and
benign tracheal tumors comprised of 0.038% of all benign
tumors (1.16% of all thoracic benign tumors).
Papilloma (3 of 14) was the most common benign
tumor followed by hemangioma (2 of 14). Remainders were
composed of various benign pathologies. Dyspnea was the
most common presenting symptom for tracheal benign tu-
mors. Except for the papilloma cases, which have great
tendency of recurrence, tumors were managed successfully
with surgical excision without recurrence. Average 11.3 num-
ber of surgeries (laser bronchoscope) were required for pap-
illoma patients with mean interval of 200.7 days between
each surgery (Table 2).
Among the 23 malignant tracheal tumors, SCCs (n 
11) and ACCs (n  9) comprised most of the malignant
tumors. SCC occurs in older age and showed male prepon-
derance (M:F, 8:3 in SCC, 2:4 in ACC) compared with ACC
(Table 3).
T stage tends to be higher in ACC compared with
squamous carcinoma. Interestingly, no lymph node metasta-
sis was observed in ACCs although SCCs showed 54.5% (6
of 11) of lymph node metastasis. Distant metastasis was
discovered in two patients at the time of diagnosis (Table 4).
Five-year overall survival rate was 41.1% for SCC and
45.7% for ACC. However, no statistically significant differ-
ence (p  0.673) was observed (Figure 1).
In SCC patients group, six patients underwent surgery,
three patients received combined modality treatment and two
patients received radiation therapy. Four ACC patients re-
ceived surgical treatment, three patients underwent combined
modality treatment and two patients received radiation ther-
apy. Five-year disease specific survival rate for surgery,
TABLE 2. Summary of the Benign Tracheal Tumors
Patient Sex/Age Chief Complaint
Sx to
Dx (mo) Final Dx Tx Tx Result
1 M/46 Dyspnea 12 Papilloma LVB, 8 times AWD
2 F/18 Dyspnea 2 Papilloma LVB, 23 times AWD
3 F/5 Dyspnea 5 Papilloma LVB, 3 times AWD
4 F/0.3 Dyspnea 2.7 Hemangioma LVB NED
5 M/14 Hemoptysis 0.33 Hemangioma LVB NED
6 F/1 Dyspnea 1 Nonspecific reactive
hyperplasia of LN
LVB NED
7 M/3 Dyspnea 36 Epithelial inclusion LMS NED
Cyst Jet ventilation
8 M/5 Dyspnea 50 Giant cell granuloma LVB NED
9 M/15 Dyspnea 5 Pleomorphic adenoma TREE NED
10 M/47 Dyspnea 11 Tuberculosis LVB NED
11 M/57 Dyspnea 12 Lipoma LVB NED
12 M/74 Dyspnea 4 Leiomyoma TREE NED
13 M/32 Dyspnea 26 Neurilemmoma TREE NED
14 F/1 Dyspnea 1 Langerhans cell histiocytosis TREE NED
LVB, laser ventilating bronchoscopy; LMS, larygomicrosurgery; TREE, tracheal resection and end to end anastomosis; AWD, alive with
disease; NED, no evidence of disease.
TABLE 3. Demographic and Pathologic Distribution of the
Malignant Tracheal Tumors
n Mean Age (yr) Range p
Overall 23 52.9 29–69
Sex 0.17
Male 14 54 39–69
Female 9 50.8 29–69
Histological type 0.047
SCC 11 55.2 39–69
ACC 9 40.7 29–66
Othersa 3 53 45–58
SCC, squamous cell carcinoma; ACC, adenoid cystic carcinoma.
a Others, 1 spindle cell sarcoma, 1 neuroendocrine carcinoma, 1 adenocarcinoma.
TABLE 1. Staging System Proposed by Bhattacharyya (2004)
Stage Definition
T
1 Primary tumor confined to trachea; size 2 cm
2 Primary tumor confined to trachea; size 2 cm
3 Spread outside the trachea but not to adjacent organs
or structures
4 Spread to adjacent organs or structures
N
0 No evidence of regional nodal disease
1 Positive regional nodal disease
Stage
I T1N0
II T2N0
III T3N0
IV T4N0 or any N1 disease
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surgery and radiation, radiation only group were 50.0%, 50%,
0% for SCC patients and 50%, 100%, 50% for ACC patients
respectively. However, no statistically significant survival
difference was observed for both pathologies. The Bhatta-
charyya’s staging system was clinically relevant in our subset
of patients (p  0.016, Figure 2).
DISCUSSION
Thirteen benign tracheal tumors showed heterogenous
pathologic distribution with relatively homogenous presenta-
tion. Papilloma was the most frequent one, though only
23.1% (3 of 13) of tracheal benign tumors fell into this
category. Two cases of hemangioma were reported and the
remaining eight were composed of various pathologies. Laser
excision using rigid brochoscopy was sufficient for tumors
with limited extensions. In four invasive tumors, open tra-
cheal resection and end to end anastomosis were required.
However, in papilloma cases, repetitive surgeries were re-
quired due to its extremely high recurrence tendency.
SCC was reported to be the most frequent pathology
followed by ACC (Table 5).6,8–10,12–14 The prevalence of
SCC in our study population was similar (47.8%, 11 of 23),
however, ACC was more frequent than any other studies
reported dealing with more than 50 cases of tracheal malig-
nancy (39.1%, 9 of 23). Ethnic difference could play a role in
this discrepancy, although a larger scale study is required to
validate this finding.
Regarding the incidence of tracheal tumors, annual
incidence was reported to be 0.6 to 3.1 among 10,000 patients
in a hospital-based study in western population.5,6,8 The
estimated annual incidence in our study population was 2.62
for malignant tumor and 3.78 for benign tumor (among
10,000 patients). This findings correlate well with the western
studies. Unfortunately, this study was not a community based
study, so we could not evaluate the annual incidence of
tracheal tumor for general population.
SCC was reported to occur mainly in men in their sixth
and seventh decades, whereas ACC is equally distributed
between the sexes and is most common in patients in their
fourth and fifth decades.7 Demographic findings in our study
was similar in age (mean age, 55.2 years in SCC, 40.1 years
in ACC) and sex (M:F, 8:3 in SCC, 3:6 in ACC).
FIGURE 1. Overall survival according to the pathology. SCC,
squamous cell carcinoma; ACC, adenoid cystic carcinoma.
FIGURE 2. Overall survival according to the clinical stage.
TABLE 4. Staging of the Malignant Tracheal Tumors
According to the Bhattacharyya
Variable
SCC
(n  11)
ACC
(n  9)
Others
(n  3)
n % n % n %
T stage
T1 6 54.5 2 22.2 2 66.7
T2 4 36.7 5 55.6 1 33.3
T3 1 9.1 2 22.2 0
N stage
N0 6 54.5 9 100 2 66.7
N1 5 45.5 0 0 1 33.3
M stage
M0 10 89.9 8 87.5 3 100
M1 1 9.1 1 12.5 0 0
SCC, squamous cell carcinoma; ACC, adenoid cystic carcinoma.
TABLE 5. Pathologic Distribution of the Malignant Tracheal
Tumors in Studies with More Than 50 Cases
Author Year Period Cases
Histology (%)
ReferenceSCC ACC Others
Kurien 1981 1957–1974 97 46 3 51 12
Manninen 1993 1967–1985 95 72 6 22 9
Gelder 1993 1968–1987 321 54 11 35 10
Yang 1997 1979–1994 67 52 8 40 13
Licht 2001 1978–1995 109 63 7 29 6
Honings 2006 1989–2002 308 53 7 40 8
Webb 2007 1945–2004 74 46 26 28 14
SCC, squamous cell carcinoma; ACC, adenoid cystic carcinoma.
Journal of Thoracic Oncology • Volume 4, Number 5, May 2009 Primary Tracheal Tumors
Copyright © 2009 by the International Association for the Study of Lung Cancer 637
There is no established staging system in American
Joint Committee for Cancer guideline. Only three stud-
ies6,11,14 suggested the guideline for staging of the tracheal
malignancy and only one study11 validated their result. Tak-
ing this into account, we adopted the Bhatakaryyaa’s staging
system. This system was proved to be clinically relevant in
our subset of patients.
Primary malignant tumors are usually treated with
surgery, endoscopic resection by various techniques, and
radiotherapy. Complete resection of tracheal tumors was
reported to be the preferred treatment that can relieve the
airway obstruction simultaneous with treating the disease.5
Surgery was also the mainstay of the treatment modality in
our study (18 of 23, 78.3%). Most patients were treated with
open approach and curative resection, however, endoscopic
removal using laser (2 of 18, 11.15%) was successfully
performed in selected early stage tumors.
Radiotherapy is indicated as an adjuvant after resection,
for tumors that are unresectable or medically inoperable, and for
palliation of severe symptoms.7 Adjuvant radiation therapy was
performed in seven cases and primary radiation therapy was
performed in unresectable cases or in patients who rejected
surgical treatment (3 of 23, 2 of 23, respectively).
Pathologic distribution was reported to be related with
the prognosis, and relatively higher survival was reported in
ACC compared with SCC (Table 6).8,15–17 In our study
population, no statistically significant survival difference was
observed between SCC and ACC. Lung metastasis was the
main cause of death in ACC patients (6 of 7, 85.7%). A larger
scale, multi-institutional or nationwide survey is warranted to
validate this survival result.
Treatment modalities clearly affect the survival. Sur-
gery proved to be superior to radiation therapy in many
studies. Five-year overall survival in surgically managed
group ranged from 41 to 57%, although only 6 to 11% of
5-year overall survival was achieved in radiation group.6,8,14
In this study, we analyzed 14 benign tracheal tumors
and 23 malignant tracheal tumors. Benign tumors predomi-
nated in children and composed of various pathologies al-
though the clinical presentation was similar. SCC was most
prevalent among malignant tumors and ACC was more fre-
quently found compared with the western population. Al-
though pathology did not affect the survival, clinical stage
was considered as the significant prognostic factors. Consid-
ering the rarity of tracheal tumors, multicenter or nationwide
study is warranted to validate these findings.
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TABLE 6. Reported Survival Rate for Malignant Tracheal
Tumors According to the Pathology
Author Year Period Pathology
No. of
Patients
Survival
(%)
Reference5-yr 10-yr
Gaissert 2004 1962–2002 ACC 101 52 29 15
Regnard 1996 1978–1992 ACC 65 73 51 16
Maziak 1996 1963–1995 ACC 32 79 51 17
Honings 2007 1989–2002 ACC 22 61 61 8
Honings 2007 1989–2002 SCC 163 12 0 8
Regnard 1996 1978–1992 SCC 94 47 36 16
Gaissert 2004 1962–2002 SCC 90 39 18 15
SCC, squamous cell carcinoma; ACC, adenoid cystic carcinoma.
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